Compare CD & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CD | CRBP |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.2M | 190.3M |
| IPO Year | 2014 | 2014 |
| Metric | CD | CRBP |
|---|---|---|
| Price | $3.32 | $11.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $45.50 |
| AVG Volume (30 Days) | 243.3K | ★ 454.0K |
| Earning Date | 08-31-2023 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,867,068.00 | ★ $4,822,272.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 277.93 | 97.62 |
| 52 Week Low | $2.10 | $7.12 |
| 52 Week High | $14.10 | $20.56 |
| Indicator | CD | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 62.01 |
| Support Level | $2.96 | $7.53 |
| Resistance Level | $4.28 | $12.57 |
| Average True Range (ATR) | 0.53 | 0.56 |
| MACD | 0.04 | 0.09 |
| Stochastic Oscillator | 48.96 | 68.51 |
Chaince Digital Holdings Inc is digital fintech company providing access to the growing AI-powered infrastructure, blockchain, and digital assets. Its three core business lines include: blockchain and digital asset solutions, AI and HPC infrastructure, developing liquid cooling solutions for AI data centers and comprehensive financial services through Chaince Securities,LLC a FINRA-registered broker-dealer, and RIA.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.